Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

Abstract Background Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway overexpresses in chronic lymphocytic leukemia (CLL) cells and appears to have a significant pa...

全面介紹

書目詳細資料

Principais autores:	Atefeh Khodakarami, Mahsa Afsari Kashani, Atefeh Nazer, Armin Mahmoudsalehi Kheshti, Bentolhoda Rashidi, Vahid Karpisheh, Ali Masjedi, Shiva Abolhasani, Sepideh Izadi, Rafieh Bagherifar, Seyyed Sina Hejazian, Hamed Mohammadi, AliAkbar Movassaghpour, Abbas Ali Hosseinpour Feizi, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh
格式:	Artigo
語言:	Inglês
出版:	BMC 2023-08-01
叢編:	Cell Communication and Signaling
主題:	Chronic lymphocytic leukemia (CLL) NRF2 Cyclophosphamide Rituximab Chemo-resistance
在線閱讀:	https://doi.org/10.1186/s12964-023-01213-1
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!